Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)

BJU International

Volumn 113, Issue 3, 2014, Pages 429-436

  Krege, Susanne ^a   Rexer, Heidrun ^b   Vom Dorp, Frank ^c   De Geeter, Patrick ^d   Klotz, Theodor ^e   Retz, Margitte ^f   Heidenreich, Axel ^g   Kühn, Michael ^h   Kamradt, Joern ⁱ   Feyerabend, Susan ^j   Wülfing, Christian ^k   Zastrow, Stefan ^l   Albers, Peter ^m   Hakenberg, Oliver ⁿ   Roigas, Jan ^o   Fenner, Martin ^p   Heinzer, Hans ^q   Schrader, Mark ^r  

^a Krankenhaus Maria Hilf   (Germany)

^b Institute MeckEvidence   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d KLINIKUM KASSEL   (Germany)

^e Klinikum Weiden   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^h Department of Urology   (Germany)

ⁱ SAARLAND UNIVERSITY   (Germany)

^j UNIVERSITY OF TÜBINGEN   (Germany)

^k UNIVERSITY OF MÜNSTER   (Germany)

^l DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^m HEINRICH HEINE UNIVERSITY   (Germany)

ⁿ UNIVERSITY OF ROSTOCK   (Germany)

^o VIVANTES KLINIKUM AM URBAN   (Germany)

^p LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^q UNIVERSITY OF HAMBURG   (Germany)

^r CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

advanced urothelial cancer; chemotherapy; tyrosine kinase inhibitors; VEGFR overexpression

Indexed keywords

CISPLATIN; GEMCITABINE; PLACEBO; SORAFENIB;

ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; EDEMA; EPISTAXIS; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; HYPERTENSION; INFECTION; INTENTION TO TREAT ANALYSIS; KIDNEY FAILURE; LEUKOPENIA; MALE; METASTASIS POTENTIAL; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; REVIEW; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; VISCERAL METASTASIS; VOMITING;

ADVANCED UROTHELIAL CANCER; CHEMOTHERAPY; TYROSINE-KINASE-INHIBITORS; VEGFR-OVEREXPRESSION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; UROLOGIC NEOPLASMS;

EID: 84896694547     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12437     Document Type: Review

References (31)

1. von der Maase H, Sengelov L, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-3077
2. Bellmunt J, Guillem V, Paz-Ares L, et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 2000; 18: 3247-3255
3. Sternberg CN, de Mulder PH, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose- intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors. Eur J Cancer 2006; 42: 50-54 (Pubitemid 41814532)
4. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/ cisplatin/ gemcitabine and gemcitabine/ cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy; EORTC Intergroup Study 30987. J Clin Oncol 2012; 30: 1107-1113
5. Chow NH, Liu HS, Lee EL, et al. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res 1997; 17: 1293-1296
6. Vollmer RT, Humphrey PA, Swanson PE, et al. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2. Cancer 1998; 82: 715-723 (Pubitemid 28090284)
7. Jimenez RE, Hussain M, Bianco FJ Jr, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001; 7: 2440-2447 (Pubitemid 32751647)
8. Yang CC, Chu KC, Yeh WM,. The expression of vacular endothelial growth factor in transitional cell carcinoma of the urinary bladder is correlated with cancer progression. Urol Oncol 2004; 22: 1-6
9. Xia G, Kumar S, Hawes D, et al. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 2006; 175: 1245-1252
10. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109 (Pubitemid 39331023)
11. Murphy D, Makinnen S, Feldman M, et al. BAY 43-9006 controls tumor growth inhibition of vascular development. Clin Cancer Res 2005; 46: 2985-2989
12. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a mulitkinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signalling. Mol Cancer Ther 2008; 7: 3129-3140
13. Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/ 7days off in patients with advanced, refractory solid tumors. Ann Oncol 2005; 16: 1688-1694 (Pubitemid 41510145)
14. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965-972 (Pubitemid 46202316)
15. Flaherty KT, Schiller J, Schuchtner LM, et al. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 2008; 14: 4836-4842
16. Blumenschein GR Jr, Gatzemeier U, Fosella F, et al. Phase II multicenter uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 4274-4280
17. Przybojewska B, Jagiello A, Jalmunza P,. H-Ras, K-Ras and N-Ras gene activation in human bladder cancers. Cancer Genet Cytogenet 2000; 121: 73-77 (Pubitemid 30665745)
18. Paz-Ares LG, Biesma B, Heigener D, et al. Phase III, randomised, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 2012; 30: 3084-3092
19. Pollera CF, Ceribelli A, Crecco M, et al. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 1994; 5: 182-184 (Pubitemid 24062575)
20. Rose A, Grandoch M, vom Dorp F, et al. Stimulartory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells. Br J Pharmacol 2010; 160: 1690-1698
21. Dreicer R, Li H, Stein M, et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 2009; 115: 4090-4095
22. Sridhar SS, Winquist E, Eisen A, et al. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest New Drugs 2010; 29: 1045-1049
23. Gallagher DJ, Milowsky MI, Gerst SR, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 2010; 28: 1373-1379
24. Bellmunt J, Gonzalez-Larriba JL, Prior C, et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol 2011; 22: 2646-2653
25. Galsky MD, Hahn NM, Powles T, et al. Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer 2013; 11: 175-181
26. Hahn NM, Stadler WM, Zon RT, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol 2011; 29: 1525-1530
27. Choueiri TK, Ross RW, Jacobus S, et al. Double-blind, randomised trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol 2012; 10: 507-512
28. Milowsky MI, Iyer G, Regazzi AM, et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int 2013; 112: 462-470
29. Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitacel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007; 25: 2218-2224 (Pubitemid 46954646)
30. Lae M, Couturier J, Oudard S, et al. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 2010; 21: 815-819
31. Galsky MD, Von Hoff DD, Neubauer M, et al. Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with Her2-amplified solid tumors. Invest New Drugs 2012; 30: 695-701